$TENX

Monday’s insider buys and sells: Coal director invests $3.2M

Insider trading activity reported for US public companies includes significant purchases and sales. ADAR1 Capital bought 1.03M Tenax Therapeutics (TENX) shares for $1.81M. Kenneth Courtis acquired 15K Alpha Metallurgical (AMR) shares for $3.16M. Rex Geveden bought 5K TTM Technologies (TTMI) shares for $524.5K. Ashley McEvoy, CEO of Insulet (PODD), purchased 1.1K shares for $162.2K. Notable sales include James Wirth selling IHT shares for $1.82B, Alexander Karp selling 492K Palantir (PLTR) shares

Original reporting
Published Aug 25, 2026, 1:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 1:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$TENX
Bullish
medium confidence
Mentioned
$TENX · $AMR · $TTMI · $BFC · $PODD · $IHT
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$TENXBullishLow
01

Why it matters

Aggregated insider activity provides mixed signals; large sells may pressure stocks while buys could support them.

02

Market read

The filings highlight potential short‑term price moves for the listed tickers.

03

What to watch

Some purchases could be strategic positioning ahead of upcoming corporate events not disclosed yet.

Relevance 4/10Novelty 6/10Timing: Monday

Background

Weekly roundup of Form 4 insider transactions across multiple US‑listed companies.

Company-level read

Ticker impact

$TENXBullishMedium confidence
Context

Form 4 shows insider ADAR1 Capital Management buying $1.81M of Tenax Therapeutics shares.

Expected impact

Potential modest upside as market absorbs buying signal.

Evidence & confidence

Buy amount is sizable for a micro‑cap, but price already down 84% YTD limiting upside.

$AMRBullishMedium confidence
Context

Director Kenneth S. Courtis purchased $3.16M of Alpha Metallurgical Resources shares.

Expected impact

Short‑term price lift expected.

Evidence & confidence

Purchase size relative to float is material; market may view as endorsement.

$TTMIBullishLow confidence
Context

Director Rex D. Geveden bought 5,000 shares of TTM Technologies for $524,500.

Expected impact

Limited upside; may stabilize price.

Evidence & confidence

Purchase is modest relative to market cap.

$BFCNeutralLow confidence
Context

Director Tracy C Pearson acquired 1,024 shares of Bank First Corp for $160,737.

Expected impact

Minimal impact.

Evidence & confidence

Transaction size is tiny relative to float.

$PODDBullishMedium confidence
Context

CEO Ashley McEvoy bought 1,100 shares of Insulet Corp for $162,217.

Expected impact

Potential modest rally if market interprets as confidence.

Evidence & confidence

Executive buying is a strong signal, though amount is modest.

$IHTBearishMedium confidence
Context

CEO James F. Wirth sold 34,800 shares of Innsuites Hospitality Trust worth $1.82B.

Expected impact

Downward pressure likely.

Evidence & confidence

Sale size is massive relative to market cap.

$CHYMBearishMedium confidence
Context

DST Global Advisors sold $28.1M of Chime Financial shares.

Expected impact

Potential short‑term dip.

Evidence & confidence

Sale amount is notable for a fintech of this size.

$PLTRBearishMedium confidence
Context

CEO Alexander C. Karp sold 492,348 shares of Palantir for $86.06M.

Expected impact

Possible modest decline.

Evidence & confidence

Size is material; tax‑driven sales still signal liquidity need.

Market effects

Insider activity across healthcare, fintech, mining, and REITs may influence sector sentiment.

US market focus; no notable regional spillover.

Limited to US‑listed equities.

Counterpoint

Insider sells may be routine tax planning rather than lack of confidence.

Key entities

  • Tenax Therapeutics

    Biotech micro‑cap with recent insider buying.

  • Palantir Technologies

    Data‑analytics firm with large insider sell.

Related articles

$PLTRMedAI 8/10

Our Palantir Price Target Is Higher Than Wall Street’s

24/7 Wall St. raised its Palantir (PLTR) price target to $214.93, above Wall Street's consensus of $191.68, citing strong Q2 earnings and revenue growth. PLTR's forward P/E of 108x is compared to Snowflake (SNOW) and ServiceNow (NOW). The company raised FY2026 revenue guidance to $8.150-$8.158 billion.

$PLTRMedAI 8/10

This 1 Number Proves Why You Should Buy Palantir on Every Dip

Palantir (PLTR) reported a Rule of 40 score of 155% in Q2 FY2026, up from 145% last quarter, driven by 92.8% revenue growth and a 62% adjusted operating margin. The company generated $1.22 billion in free cash flow and raised full-year guidance. Comparatively, Snowflake (SNOW) and Salesforce (CRM) lag in growth and margins. PLTR trades at a P/E of 251, but strong fundamentals may justify its valuation.

$TTMIMedAI 8/10

TTMI vs. AMKR: Which Semiconductor Stock Should You Buy Now?

TTM Technologies (TTMI) and Amkor Technology (AMKR) are semiconductor companies with exposure to AI infrastructure. TTMI reported Q2 2026 sales of $1B, up 37%, with strong data center growth. AMKR saw Q2 2026 revenues rise 26% to $1.9B. TTMI expects 15-20% organic growth in 2027-2028, while AMKR projects $1.95-2.05B in Q3 2026 sales. TTMI's stock is up 77.6% YTD, outperforming AMKR's 24.4%.

$PLTRHigh

Why is Palantir Technologies stock rallying today?

Palantir Technologies (PLTR) stock rose 3.8% to $184.32 after William Blair reiterated its Outperform rating, citing progress in the Maven Smart System and Pentagon contracts. The Defense Department proposed $244M in additional funding. Palantir reported 93% YoY revenue growth in Q2 and raised full-year guidance to $8.154B. Analysts have raised price targets, and the broader market showed gains.